Risk/Benefit assessment of thrombotic thrombocytopenic events after Janssen COVID-19 vaccines : Applying evidence to recommendation framework

Details

• Personal Author:
  Oliver, Sara E.
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group.
• Description:
  During the ACIP meeting, the numbers presented were risks and benefits per two million vaccine doses; numbers have been updated here to reflect risks and benefits per one million vaccine doses.
  
  06-COVID-Oliver-508.pdf
  
  
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines/adverse Effects Patient Safety Safety-Based Drug Withdrawals Thrombocytopenia Thrombosis
• Series:
  ACIP: Coronavirus Disease 2019 (COVID-19)
• Document Type:
  Still Image
• Name as Subject:
  ACIP meeting: 2021 Apr. 23 ; Janssen COVID-19 Vaccine ; Coronavirus Infections/prevention & control ; COVID-19 Vaccines/adverse effects ; Patient Safety ; Safety-Based Drug Withdrawals ; Thrombocytopenia ; Thrombosis ; ACIP meeting: 2021 Apr. 23 ; Janssen COVID-19 Vaccine ; Coronavirus Infections/prevention & control ; COVID-19 Vaccines/adverse effects ; Patient Safety ; Safety-Based Drug Withdrawals ; Thrombocytopenia ; Thrombosis
• Genre:
  Presentation ; Conference Publications
• Volume:
  202105
• Issue:
  0100106
• Collection(s):
  Advisory Committee on Immunization Practices (ACIP)
• Main Document Checksum:
  urn:sha-512:d5b8880c184d86c532ec1ce87c2196ee54423948909535fbcca2a5bf9a203832e6c1057e67d6fc845d70cf02c28d24d5bd272dbb68b43e6260d820759de1c3e5
• Download URL:
  https://stacks.cdc.gov/view/cdc/107511/cdc_107511_DS1.pdf
• File Type:
  [PDF - 4.55 MB ]